Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags.
Gerald Appel, MD
Advertisement
Articles by Gerald Appel, MD
Learn how targeted-release budesonide treats IgA nephropathy, cutting proteinuria and slowing GFR decline with fewer steroid side effects.
Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons.
New KDIGO updates push earlier IgA nephropathy treatment, targeting immune pathways and nephron protection to cut proteinuria and slow eGFR decline.
Explore KDIGO 2025 IgA nephropathy shifts: treat earlier at proteinuria >0.5 g/day, dual-pathway therapy aims to preserve GFR.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5